Marina ZICHE

foto Marina Ziche
Biosketch and CV

Medical Doctor, Univ. Florence Medical School (1977)

ECFMG examination, USA (1980)

Board Member of Endocrinology, Univ. Florence Medical School (1983)


1979-81 Fogarty fellow, Lab. Pathophysiology, NCI-NIH, USA

1984-98 Senior Research Scientist, Dept. Preclinical and Clinical Pharmacology Univ. Florence.

1990-98 Visiting Professor, Microcirculation Research Institute, Dept. Medical Physiology, Texas A&M University,  College Station, Texas, USA.

1998-2000: Associate Professor, Inst. Pharmacological Sciences, Univ. Siena.

2000-01 Visiting Professor, University of Texas Southwestern Medical Center, Dallas, TX (USA)

2000-present: Full Professor of Pharmacology, Univ. Siena.

Research Interests
  • Pharmacology of angiogenesis and microcirculation
  • Evaluation of the cellular and molecular mechanisms of physiologic and pathologic angiogenesis, particularly in inflammatory, degenerative and neoplastic diseases
  • Characterization of pro- and antiangiogenic factors in the disease progression and for therapeutic exploitation
  • Design and evaluation of new pharmacological strategies for the control of angiogenesis
Research Group

Federica Finetti

Erika Terzuoli

Chiara Lucchetti

Raffaella Solito

Lorenzo Bazzani

Teaching Activities

2013-2014: “Pharmacology”, Biological Sciences 

2012-14: “Pharmacology and Pharmacotherapeutics”, Pharmacy

Coordinator of the II level Master on “Governo clinico del farmaco e dispositivo medico”

Selected Publications
  1. Corti F, Finetti F, Ziche M, Simons M. The Syndecan-4/Protein Kinase Cα Pathway Mediates Prostaglandin E2-induced Extracellular Regulated Kinase (ERK) Activation in Endothelial Cells and Angiogenesis in Vivo. J. Biol. Chem. 288(18):12712-21 (2013)
  2. Donnini S, Finetti F, Francese S, Boscaro F, Dani FR, Maset F, Frasson R, Palmieri M, Pazzagli M, De Filippis V, Garaci E, Ziche M. A novel protein from the serum of Python sebae, structurally homologous with type-γ phospholipase A(2) inhibitor, displays antitumour activity. Biochem J. 440(2):251-62 (2011)
  3. Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M, Melillo G. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res. 70(17):6837-48 (2010)
  4. Terzuoli E, Donnini S, Giachetti A, Iñiguez MA, Fresno M, Melillo G, Ziche M.  Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin. Cancer  Res. 16(16):4207-16 (2010)
  5. Monti M, Donnini S, Giachetti A, Mochly-Rosen D, Ziche M. deltaPKC inhibition  or varepsilonPKC activation repairs endothelial vascular dysfunction by regulating eNOS post-translational modification. J. Mol. Cell. Cardiol. 48(4):746-56 (2010)
  6. Finetti F, Donnini S, Giachetti A, Morbidelli L, Ziche M. Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway. Circ. Res. 105(7):657-66 (2009)
  7. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J. Biol. Chem. 283(4):2139-46 (2008)
  8. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche  M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90(8):587-96 (1998)
  9. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J. Biol. Chem. 273(7):4220-6 (1998)
  10. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99(11):2625-34. ( 1997).